DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Namenda (Memantine Hydrochloride) - Summary



Namenda® Tablets/Oral Solution
(memantine hydrochloride)

NAMENDA™ (memantine hydrochloride) is an orally active NMDA receptor antagonist.

NAMENDA (memantine hydrochloride) is indicated for the treatment of moderate to severe dementia of the Alzheimer's type.

See all Namenda indications & dosage >>


Media Articles Related to Namenda (Memantine)

Alzheimer's drug may reduce the urge to binge eat
Source: Obesity / Weight Loss / Fitness News From Medical News Today [2014.11.18]
The Alzheimer's drug memantine may perform double-duty helping binge eaters control their compulsion.

Gout May Protect Against Alzheimer's Disease
Source: MedPage Today Neurology [2014.11.21]
(MedPage Today) -- Study showed AD incidence higher over 5 years for patients without gout.

Self-reported sleep disturbances are linked to higher risk for Alzheimer's disease in men
Source: Sleep / Sleep Disorders / Insomnia News From Medical News Today [2014.10.29]
In a new study, researchers from Uppsala University demonstrate that elderly men with self-reported sleep disturbances run a higher risk of developing Alzheimer's disease than men without...

Laying siege to beta-amyloid, the key protein in Alzheimer's disease
Source: Huntingtons Disease News From Medical News Today [2014.10.06]
The peptide - a small protein - beta-amyloid is strongly associated with Alzheimer's disease; however, researchers are still looking for unequivocal proof that this peptide is the causal agent of the...

Alzheimer's Disease
Source: MedicineNet First Aid Specialty [2014.08.05]
Title: Alzheimer's Disease
Category: Symptoms and Signs
Created: 8/5/2014 2:43:00 PM
Last Editorial Review: 8/5/2014 2:43:52 PM

more news >>

Published Studies Related to Namenda (Memantine)

The sustained mood-stabilizing effect of memantine in the management of treatment resistant bipolar disorders: Findings from a 12-month naturalistic trial. [2012.01]
BACKGROUND: We have recently provided preliminary clinical observations indicating that memantine, as augmenting agent, was associated with a meaningful antimanic and mood-stabilizing effect in treatment-resistant bipolar disorders. To further investigate the therapeutic and prophylactic action of the drug we administered memantine, as augmenting agent, to 40 treatment-resistant bipolar disorder patients, monitored and evaluated for 12months... CONCLUSIONS: The results confirm our previous observations and strongly suggest that memantine, as augmenting agent, was associated with a clinically substantial antimanic and sustained mood-stabilizing effect, with excellent safety and tolerability profile. Copyright (c) 2011 Elsevier B.V. All rights reserved.

Donepezil and memantine for moderate-to-severe Alzheimer's disease. [2012]
disease... CONCLUSIONS: In patients with moderate or severe Alzheimer's disease, continued

Memantine and functional communication in Alzheimer's disease: results of a 12-week, international, randomized clinical trial. [2012]
Post hoc analyses suggest that memantine treatment may provide communication-related benefits in patients with Alzheimer's disease (AD). In this 12-week, international, randomized, double-blind, placebo-controlled trial of memantine (10 mg bid), the functional communication abilities of patients with AD (MMSE range: 10-19) were assessed using the Functional Linguistic Communication Inventory (FLCI; primary measure)...

A placebo controlled trial of memantine as an adjunct to oral naltrexone for opioid dependence. [2011.12.01]
BACKGROUND: Preclinical findings suggest that the inhibition of NMDA glutamatergic neurotransmission may have beneficial effects in the treatment of opioid dependence. AIMS: We hypothesized that memantine, a low-potency, uncompetitive NMDA receptor antagonist, would be safe and effective when used as an adjunct to oral naltrexone in the treatment of opioid dependence, particularly in preventing relapse to opiate use in detoxified individuals... CONCLUSION: Thus, the efficacy of memantine 30 or 60 mg/day as an adjunct to oral naltrexone for the treatment of opiate dependence was not supported. Copyright (c) 2011 Elsevier Ireland Ltd. All rights reserved.

Alzheimer's disease - input of vitamin D with mEmantine assay (AD-IDEA trial): study protocol for a randomized controlled trial. [2011.10.20]
ABSTRACT: BACKGROUND: Current treatments for Alzheimer's disease and related disorders (ADRD) are symptomatic and can only temporarily slow down ADRD...

more studies >>

Clinical Trials Related to Namenda (Memantine)

Memantine and Intensive Speech-Language Therapy in Aphasia [Completed]

- Aphasia, the loss or impairment of language caused by brain damage, is one of the most

devastating cognitive impairments of stroke. Aphasia can be treated with combination of speech-language therapy and drugs. Conventional speech-language therapy in chronic aphasic subjects is of little help and several drugs have been studied with limited success. Therefore other therapeutic strategies are warranted.

- Recent data suggest that drugs (memantine) acting on the brain chemical glutamate may

help the recovery of cognitive deficits, included language, in subjects with vascular dementia. The present study examines the safety profile and efficacy of memantine paired with intensive language therapy in subjects with stroke-related chronic aphasia (more than 1 yr. of evolution).

Effect of Namenda on Short Term Memory and Attention in Patients With Mild to Moderate Traumatic Brain Injury [Recruiting]
The purpose of this study is to determine whether memantine (Namenda) improves memory and attention in patients with mild to moderate traumatic brain injury.

A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease [Recruiting]
The primary study hypothesis is that compared with placebo, alpha-tocopherol, memantine (Namenda), or the combination will significantly delay clinical progression in mild to moderately demented patients with Alzheimer's disease.

Efficacy and Safety of the Use of Memantine for Preserving Cognition in Adult Patients With Epilepsy [Not yet recruiting]
People with epilepsy often experience problems with their memories and other thinking skills that get worse over time. The investigators hope to learn more about whether a drug called memantine can help improve or stabilize (keep the same) memory and other thought processes in people with epilepsy by blocking a chemical that is released in the brain during seizures. The investigators also want to see if memantine changes the frequency (how often) people with epilepsy have seizures. Memantine is currently approved by the United States Food and Drug Administration (FDA) for treatment of patients with Alzheimer's disease.

Does Memantine Improve Verbal Memory Task Performance in Subjects With Partial Epilepsy and Memory Dysfunction? [Recruiting]
Many patients with epilepsy have memory deficits in the setting of otherwise normal intelligence. Unfortunately, the treatment options for memory dysfunction in patients with epilepsy are limited. The investigators are conducting a study to evaluate the effects of memantine for the treatment of verbal memory dysfunction in subjects with localization-related seizures. The study involves randomization to memantine therapy or placebo, with cognitive testing and EEG pre- and post-treatment, as well as after an open-label memantine treatment phase.

The primary aim of this study is to evaluate the efficacy of memantine for the treatment of verbal memory dysfunction in subjects with left temporal lobe epilepsy. The investigators expect that verbal memory task performance will improve in those taking memantine, but not in those taking a placebo.

The investigators propose that the expected benefit of memantine is specific to verbal memory in subjects with left temporal lobe seizures, rather than representing an overall improvement in cognitive function. The investigators expect no improvement on other cognitive tasks in either the memantine or placebo groups.

The investigators will evaluate whether subjects with left temporal lobe epilepsy and memory difficulties have self-reported improvement in memory while taking memantine. The investigators expect improvement of self-rated memory function on the Quality of Life in Epilepsy Patient Inventory (QOLIE-89) in the memantine group, but no change on this scale in the placebo group.

more trials >>

Reports of Suspected Namenda (Memantine) Side Effects

Confusional State (7)Dizziness (5)Abnormal Behaviour (5)Tremor (5)Movement Disorder (4)Drug Interaction (4)OFF Label USE (4)Asthenia (4)Thinking Abnormal (3)Balance Disorder (3)more >>

Page last updated: 2014-11-21

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014